NASDAQ:NERV Minerva Neurosciences (NERV) Stock Price, News & Analysis $2.10 +0.29 (+16.07%) Closing price 04:00 PM EasternExtended Trading$2.08 -0.03 (-1.43%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Minerva Neurosciences Stock (NASDAQ:NERV) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Minerva Neurosciences alerts:Sign Up Key Stats Today's Range$1.75▼$2.1150-Day Range$1.38▼$2.1152-Week Range$1.15▼$3.38Volume128,413 shsAverage Volume22,659 shsMarket Capitalization$12.68 millionP/E Ratio2.57Dividend YieldN/APrice Target$5.00Consensus RatingHold Company Overview Minerva Neurosciences, Inc. (NASDAQ: NERV) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative therapies for central nervous system (CNS) disorders. Founded in 2004 and headquartered in Boston, Massachusetts, Minerva’s research platform leverages insights into neurotransmitter systems to identify novel small molecules and biologics aimed at unmet medical needs in psychiatry and neurology. The company’s lead candidate, seltorexant (MIN-202), is a selective orexin-2 receptor antagonist being evaluated for the treatment of major depressive disorder and associated sleep disturbances. In parallel, Minerva is advancing MIN-117, a multimodal serotoninergic and adrenergic agent designed to address depression in patients who have shown inadequate response to existing therapies. Preclinical programs targeting cognitive impairment and neurodegenerative indications further diversify the company’s pipeline. Minerva Neurosciences operates across North America and Europe, conducting its clinical trials in diverse patient populations to ensure broad applicability of its results. The company maintains strategic collaborations with contract research organizations and academic centers to support its Phase 1–3 studies. Manufacturing partnerships in the United States and Europe enable scalable production of investigational compounds. Under the leadership of President and Chief Executive Officer Umer Raffat, Minerva has built a management team with deep expertise in CNS drug development, regulatory affairs and commercial strategy. Since its initial public offering in 2015, the company has pursued a disciplined approach to advancing its pipeline, aiming to bring first-in-class therapies to patients with limited treatment options in the psychiatric and neurological space.AI Generated. May Contain Errors. Read More Minerva Neurosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks84th Percentile Overall ScoreNERV MarketRank™: Minerva Neurosciences scored higher than 84% of companies evaluated by MarketBeat, and ranked 172nd out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingMinerva Neurosciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageMinerva Neurosciences has received no research coverage in the past 90 days.Read more about Minerva Neurosciences' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Minerva Neurosciences are expected to decrease in the coming year, from ($0.30) to ($2.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Minerva Neurosciences is 2.57, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.90.Price to Earnings Ratio vs. SectorThe P/E ratio of Minerva Neurosciences is 2.57, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 20.18.Read more about Minerva Neurosciences' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.50% of the float of Minerva Neurosciences has been sold short.Short Interest Ratio / Days to CoverMinerva Neurosciences has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Minerva Neurosciences has recently decreased by 12.46%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMinerva Neurosciences does not currently pay a dividend.Dividend GrowthMinerva Neurosciences does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.89 Percentage of Shares Shorted0.50% of the float of Minerva Neurosciences has been sold short.Short Interest Ratio / Days to CoverMinerva Neurosciences has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Minerva Neurosciences has recently decreased by 12.46%, indicating that investor sentiment is improving significantly. News and Social Media2.0 / 5News Sentiment0.58 News SentimentMinerva Neurosciences has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.97 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Minerva Neurosciences this week, compared to 0 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Minerva Neurosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.60% of the stock of Minerva Neurosciences is held by insiders.Percentage Held by InstitutionsOnly 34.56% of the stock of Minerva Neurosciences is held by institutions.Read more about Minerva Neurosciences' insider trading history. Receive NERV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Minerva Neurosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address NERV Stock News HeadlinesMinerva CEO navigates 'nightmare' lab market to secure new HQ in WoburnJuly 16 at 6:03 AM | bizjournals.comMinerva University Named World's Most Innovative University for Fourth Consecutive YearJuly 15 at 9:50 AM | uk.finance.yahoo.comThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.July 16 at 2:00 AM | Crypto Swap Profits (Ad)Helsinki Cup: Minerva Academy in Round-16 with thumping 7-0 winJuly 14 at 6:51 PM | msn.comMinerva Neurosciences Inc. (NERV) Stock Price Today - WSJJuly 11, 2025 | wsj.comMinerva registers fourth win in Helsinki CupJuly 10, 2025 | msn.comHelsinki Cup: Minerva Academy logs twin victoriesJuly 10, 2025 | msn.comMinerva High School Athletic Hall of Fame announces Class of 2025 membersJuly 10, 2025 | msn.comSee More Headlines NERV Stock Analysis - Frequently Asked Questions How have NERV shares performed this year? Minerva Neurosciences' stock was trading at $2.22 at the beginning of the year. Since then, NERV stock has decreased by 5.2% and is now trading at $2.1050. How were Minerva Neurosciences' earnings last quarter? Minerva Neurosciences, Inc (NASDAQ:NERV) announced its earnings results on Tuesday, May, 13th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.07) by $0.57. When did Minerva Neurosciences' stock split? Shares of Minerva Neurosciences reverse split on Tuesday, June 21st 2022.The 1-8 reverse split was announced on Tuesday, June 21st 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, June 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. How do I buy shares of Minerva Neurosciences? Shares of NERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Minerva Neurosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Minerva Neurosciences investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Meta Platforms (META), NIO (NIO), TherapeuticsMD (TXMD), Inovio Pharmaceuticals (INO) and VBI Vaccines (VBIV). Company Calendar Last Earnings5/13/2025Today7/16/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NERV CIK1598646 Webwww.minervaneurosciences.com Phone(617) 600-7373FaxN/AEmployees9Year Founded2007Price Target and Rating Average Price Target for Minerva Neurosciences$5.00 High Price Target$5.00 Low Price Target$5.00 Potential Upside/Downside+146.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)$0.82 Trailing P/E Ratio2.47 Forward P/E RatioN/A P/E GrowthN/ANet Income$1.44 million Net MarginsN/A Pretax MarginN/A Return on Equity-20.68% Return on Assets15.73% Debt Debt-to-Equity RatioN/A Current Ratio9.21 Quick Ratio9.21 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$0.24 per share Price / Cash Flow8.52 Book Value($3.67) per share Price / Book-0.55Miscellaneous Outstanding SharesN/AFree FloatN/AMarket Cap$12.45 million OptionableNot Optionable Beta-0.34 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:NERV) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredIs this secretive Asian company trying to take over Bitcoin?A mysterious Asian conglomerate is buying billions in Bitcoin — but one legendary trader says that’s the wrong...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Minerva Neurosciences, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Minerva Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.